A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL

Phase 2

Recruiting

• Conditions: Chronic Lymphocytic Leukemia
• Interventions: Drug: FCR and Ibrutinib; Drug: BR and Ibrutinib; Drug: Ibrutinib and Thalidomide

• Registration Number: NCT03980002
• Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Brief Summary

This is a prospective multicenter phase 2 study designed with the purpose to evaluate the response rate and safety of treatment with FCR/BR alternating with ibrutinib in treatment-naive patients with chronic lymphocytic leukemia.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-05-15
• Status Verified: 2019-06
• Study First Submitted: 2019-06-06
• Study First Submitted QC: 2019-06-06
• Last Update Submitted: 2019-06-06
• Study First Posted: 2019-06-10
• Last Update Posted: 2019-06-10
• Primary Completion: 2022-12-15
• Study Completion: 2027-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Men or women ≥ 18 years and ≤ 75 of age.

2. Diagnosis of CLL/SLL that meets IWCLL diagnostic criteria.

3. Treatment-naive patients. Those patients received short-term substandard treatment are permitted if meet all the items listed below:

   1. Untreated with combined chemotherapy such as CHOP ,COP and so on.
   2. Unteated with chemotherapy regimens including fludarabine and bendamustine.
   3. Unteated with Ibrutinib.
   4. If treated with chlorambucil or cyclophosphamide,should less than 3 weeks.
   5. If treated with interferon, should less than 6 months.
   6. No objective response are achieved (PR or CR).

4. CLL/SLL requiring treatment as defined by at least one of the following criteria:

   1. Development of, or worsening of, anemia to Hb<100g/L (non-hemolytic) .
   2. Development of, or worsening of, thrombocytopenia to PLT<100,000/L.
   3. Massive (≥ 6 cm below left costal margin), progressive or symptomatic splenomegaly.
   4. Massive nodes (≥ 10 cm in longest diameter), or progressive or symptomatic lymphadenopathy .
   5. Progressive lymphocytosis with an increase of > 50% over a 2-month period or lymphocyte-doubling time of < 6 months. Lymphocyte-doubling time may be obtained by linear regression extrapolation of absolute lymphocyte counts obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In patients with initial blood lymphocyte counts of < 30,000/L, LDT should not be used as a single parameter to define treatment indication. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL/SLL (eg, infection, use glucocorticoid) should be excluded. f)Symptomatic or functional extranodal sites involved s (eg. Skin,kidney, lungs and so on).

   g)Constitutional symptoms, defined as any 1 or more of the following disease-related symptoms or signs: i. Unintentional weight loss of ≥ 10% within the previous 6 months ii.Significant fatigue (ie, inability to work or perform usual activities)

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

6. Expected to survival period for 3 months or more.

Exclusion Criteria

1. History of malignant tumour except CLL in the past 1year(including active central nervous system (CNS) involvement with lymphoma).
2. Transformed to large cell lymphoma manifested by clinical evidence, or progressed to prolymphocytic leukemia(PLL).
3. Have active autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura, and require treatment.
4. Inadequate hepatic and renal function defined as: AST and ALT >4.0 x upper limit of normal (ULN), bilirubin >2.0 x upper limit of normal (ULN), Adequate renal function defined by serum creatinine >1.5 x upper limit of normal (ULN),unrelated to lymphoma.
5. Severe or uncontrolled infection.
6. Central nervous system (CNS) dysfunction with clinical manifestation.
7. Other serious medical diseases that may affect the study（eg. Uncontrolled diabetes, gastric ulcer, other severe cardiopulmonary disease),and final decided by the investigator.
8. Ongoing and uncontrolled bleeding
9. History of major life-threatening bleeding, especially due to irreversible cause.
10. Requirement for continuous anticoagulation drugs.
11. Major surgery within 30 days(excluding lymph node biopsy).
12. Pregnant or Lactating women, or women of reproductive age refusal to take contraceptive measures.
13. Allergy to any drug used in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
FCR/BR alternating with ibrutinib	FCR and Ibrutinib	FCR/BR→ ibrutinib✖️3months→FCR/BR→ ibrutinib✖️3months→FCR/BR→Maintenance therapy
FCR/BR alternating with ibrutinib	BR and Ibrutinib	FCR/BR→ ibrutinib✖️3months→FCR/BR→ ibrutinib✖️3months→FCR/BR→Maintenance therapy
FCR/BR alternating with ibrutinib	Ibrutinib and Thalidomide	FCR/BR→ ibrutinib✖️3months→FCR/BR→ ibrutinib✖️3months→FCR/BR→Maintenance therapy

Primary Outcome Measures

Name	Time	Method
CRR	3 months after completion of induction therapy	Rate of complete remission

Secondary Outcome Measures

Name	Time	Method
DoR	5 years	Duration of Response
ORR	3 months after completion of induction therapy	Overall Response Rate
OS	5 years	Overall survival
PFS	5 years	Progression-free survival
MRD negative rate	3 months after completion of induction therapy	the rate of undetectable tumor cells in bone marrow and/or peripheral blood by multicolor flow cytometry
Treatment-related side effects	10 months

Trial Locations

Locations (1)

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College; 🇨🇳 Tianjin, Tianjin, China